The potential therapeutic effect of nor-NOHA and L-NAME in breast cancer treatment

N. Avtandilyan, A. Trchounian

IJunior researcher, PhD, Research Institute of Biology, Yerevan State University, Yerevan, Armenia, II PhD, D.Sc., Professor, Head, Department of Biochemistry, Microbiology and Biotechnology, Yerevan State University, Yerevan, Armenia

What kind of therapeutic effect nor-NOHA and L-NAME in breast anticancer treatment have?
Rats (Wistar, 90-120 g, female) were divided into 7 groups (control (C), saline, C_{L-NAME}, C_{nor-NOHA}, DMBA, DMBA+nor-NOHA and DMBA+L-NAME, n=7).
DMBA was administrated (i.g.) in single dose (20 mg/ml oil). L-NAME was injected (i.p.) for 5 weeks (after 10 days of DMBA, every 3^{th} day) in dose of 30 mg/kg body-weight in 0.25 ml saline.

Histopathological alteration in DMBA group (2-4 tumors, 0.3-0.8 cm) in 20^{th} week has revealed the invasive ductal and invasive lobular carcinoma, in DMBA+nor-NOHA group (0-2 tumors, 0.1-0.3 cm) - only lobular carcinoma in situ, and in DMBA+L-NAME group (0-2 tumors, 0.1-0.4 cm) - only noninvasive ductal carcinoma. There was a difference in the timings of the deaths in DMBA (1 in 12^{th} week), DMBA+L-NAME and DMBA+nor-NOHA groups (1 in 17^{th} week). We conclude that inhibition of NOS and arginase influence on tumor growth, pathological progression and death rate.